TIGIT and neoplasm: Blockade of TIGIT and other immune checkpoints relies on the activated immune cells to eradicate tumors, which means that tumor-infiltrating lymphocytes (TILs) play a pivotal role in this process, thereby limiting the applicability of this therapy in immunosuppressed patients and ‘cold’ TME [8].